Head of Investor Relations
Cardiff Oncology, Inc. (CRDF)Head of Investor Relations
Vir Biotechnology, Inc. (VIR)Equibles does not estimate personal net worth.
Get an email with a short summary when Cardiff Oncology, Inc. publishes a filing, an earnings call transcript or a press release.
Get CRDF alertsKiki Patel is recorded as Head of Investor Relations at Cardiff Oncology, Inc. (CRDF) and Head of Investor Relations at Vir Biotechnology, Inc. (VIR). Kiki Patel has spoken on 4 earnings calls across 2 companies, most recently for Vir Biotechnology, Inc. on August 5, 2026. Those appearances were for Vir Biotechnology, Inc. (VIR) and Cardiff Oncology, Inc. (CRDF). Vir Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Cardiff Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vir Biotechnology, Inc. includes Marianne De Backer, MSc, Ph.D., MBA (CEO and Board Member), Aziz Sawaf (CFO), Brent Sabatini (CFO) and 7 others.
“Earlier today, we issued a press release reporting our second quarter 2026 financial results and corporate update. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws.”
“Earlier today, we issued a press release reporting our first quarter 2026 financial results and corporate update. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws.”
“Earlier today, we issued three press releases, including a joint release with Estellas announcing a strategic collaboration with our PSMA-directed T-cell engager, VIR 5500, a second release reporting the Phase 1 VIR 5500 data that was presented at ASCO GU, and a third release reporting our fourth quarter and year-end…”
“Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander; and Chief Financial Officer, Jamie Levine.”
Biotechnology · Healthcare
Head of Investor Relations
Biotechnology · Healthcare
Head of Investor Relations
